Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprokiren SCHEMBL7530263 | 1.00 | REN (0.61) | REN | |
| SCHEMBL7534258 | 0.94 | REN (0.54) | REN | |
| SCHEMBL7436746 | 0.94 | REN (0.55) | REN | |
| SCHEMBL7534571 | 0.94 | REN (0.57) | REN | |
| SCHEMBL7344088 | 0.94 | REN (0.62) | REN | |
| SCHEMBL7335680 | 0.93 | REN (0.63) | REN | |
| SCHEMBL7535138 | 0.93 | REN (0.63) | REN | |
| SCHEMBL7532148 | 0.93 | REN (0.51) | REN | |
| SCHEMBL7336215 | 0.93 | REN (0.61) | REN | |
| SCHEMBL9286964 | 0.91 | REN (0.59) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| WO-2020018785-A1 | METHODS OF TREATING ANGIOEDEMA | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2020-01-23 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20120220636-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F.S.P.A. (IT) | 2012-08-30 | — | — | US | claimed |
| EP-2480224-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2012-08-01 | — | — | EP | claimed |
| CN-102573827-A | Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases | ACRAF | 2012-07-11 | — | — | CN | claimed |
| WO-2011036047-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-03-31 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2007019448-A2 | NITRIC OXIDE ENHANCING ANGIOTENSIN II ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | claimed |
| WO-2006102071-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| WO-2006093864-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING NITRIC OXIDE ENHANCING GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-08 | — | — | WO | claimed |
| WO-2006091716-A2 | NITRIC OXIDE ENHANCING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-20060189603-A1 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2006-08-24 | — | — | US | claimed |
| EP-0509354-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 2000-08-23 | — | — | EP | claimed |
| US-5393875-A | Hypotensive, cardiotonic and antiischemic agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0509354-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220636-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | ACE, ACE2, CCL11 | REN 14/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | REN 3/4885 |
| US-20060189603-A1 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NOS1, NOS3, REN | REN 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.